These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 9098667

  • 1. Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.
    Goa KL, Bryson HM, Markham A.
    Drugs; 1997 Apr; 53(4):700-25. PubMed ID: 9098667
    [Abstract] [Full Text] [Related]

  • 2. Safety profile of sparfloxacin in the treatment of respiratory tract infections.
    Rubinstein E.
    J Antimicrob Chemother; 1996 May; 37 Suppl A():145-60. PubMed ID: 8737134
    [Abstract] [Full Text] [Related]

  • 3. Levofloxacin and sparfloxacin: new quinolone antibiotics.
    Martin SJ, Meyer JM, Chuck SK, Jung R, Messick CR, Pendland SL.
    Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
    [Abstract] [Full Text] [Related]

  • 4. Gatifloxacin: a review of its use in the management of bacterial infections.
    Perry CM, Ormrod D, Hurst M, Onrust SV.
    Drugs; 2002 Mar; 62(1):169-207. PubMed ID: 11790160
    [Abstract] [Full Text] [Related]

  • 5. Sparfloxacin: a review.
    Schentag JJ.
    Clin Ther; 2000 Apr; 22(4):372-87; discussion 371. PubMed ID: 10823360
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the in vitro activity of and pathogen responses to sparfloxacin with those of other agents in the treatment of respiratory tract, urinary tract, and skin and skin-structure infections.
    Dowzicky M, Nadler H, Dorr MB, Acusta A, Talbot GH.
    Clin Ther; 1999 May; 21(5):790-805; discussion 789. PubMed ID: 10397375
    [Abstract] [Full Text] [Related]

  • 7. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
    Balfour JA, Lamb HM.
    Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS, Ahlén S.
    Chemotherapy; 1993 Jan; 39(1):32-5. PubMed ID: 8383030
    [Abstract] [Full Text] [Related]

  • 9. A critical review of the fluoroquinolones: focus on respiratory infections.
    Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, Smith H, Hoban DJ.
    Drugs; 2002 Jan; 62(1):13-59. PubMed ID: 11790155
    [Abstract] [Full Text] [Related]

  • 10. Safety profile of sparfloxacin, a new fluoroquinolone antibiotic.
    Lipsky BA, Dorr MB, Magner DJ, Talbot GH.
    Clin Ther; 1999 Jan; 21(1):148-59. PubMed ID: 10090432
    [Abstract] [Full Text] [Related]

  • 11. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
    Croom KF, Goa KL.
    Drugs; 2003 Jan; 63(24):2769-802. PubMed ID: 14664657
    [Abstract] [Full Text] [Related]

  • 12. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ, Jung R, Garvin CG.
    Drug Saf; 2001 Jan; 24(3):199-222. PubMed ID: 11347723
    [Abstract] [Full Text] [Related]

  • 13. In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens.
    Baquero F, Cantón R.
    J Antimicrob Chemother; 1996 May; 37 Suppl A():1-18. PubMed ID: 8737121
    [Abstract] [Full Text] [Related]

  • 14. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
    Langtry HD, Lamb HM.
    Drugs; 1998 Sep; 56(3):487-515. PubMed ID: 9777318
    [Abstract] [Full Text] [Related]

  • 15. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group.
    Aubier M, Verster R, Regamey C, Geslin P, Vercken JB.
    Clin Infect Dis; 1998 Jun; 26(6):1312-20. PubMed ID: 9636854
    [Abstract] [Full Text] [Related]

  • 16. [In vitro comparative activity (E test) of sparfloxacin and other 8 antimicrobial agents against bacteria isolated from patients with respiratory infections acquired in the community].
    Prado V, Trucco O, Nina A, Salamanca L, Juliet C, Braun S.
    Rev Med Chil; 1995 Nov; 123(11):1394-1401. PubMed ID: 8733283
    [Abstract] [Full Text] [Related]

  • 17. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study.
    Donowitz GR, Brandon ML, Salisbury JP, Harman CP, Tipping DM, Urick AE, Talbot GH.
    Clin Ther; 1997 Nov; 19(5):936-53. PubMed ID: 9385482
    [Abstract] [Full Text] [Related]

  • 18. In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae.
    Kaku M, Ishida K, Irifune K, Mizukane R, Takemura H, Yoshida R, Tanaka H, Usui T, Tomono K, Suyama N.
    Antimicrob Agents Chemother; 1994 Apr; 38(4):738-41. PubMed ID: 8031039
    [Abstract] [Full Text] [Related]

  • 19. Levofloxacin: an updated review of its use in the treatment of bacterial infections.
    Hurst M, Lamb HM, Scott LJ, Figgitt DP.
    Drugs; 2002 Apr; 62(14):2127-67. PubMed ID: 12269858
    [Abstract] [Full Text] [Related]

  • 20. Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infections.
    Lipsky BA, Miller B, Schwartz R, Henry DC, Nolan T, McCabe A, Magner DJ, Talbot GH.
    Clin Ther; 1999 Apr; 21(4):675-90. PubMed ID: 10363733
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.